00:50 , Jan 5, 2019 |  BC Extra  |  Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
23:44 , Nov 19, 2018 |  BC Extra  |  Company News

Management tracks: Brickell, Genevant

Dermatology company Brickell Biotech Inc. (Boulder, Colo.) hired Robert Brown as CEO, effective Jan. 1. He will replace co-founder and CEO Reginald Hardy, who will remain on the board and serve as special adviser to...
22:21 , Aug 30, 2018 |  BC Extra  |  Company News

Management tracks: Lilly, Kiadis

Eli Lilly and Co. (NYSE:LLY) said SVP and President of Lilly Oncology Sue Mahony will retire, effective Aug. 31. She is succeeded by Anne White, who is VP of portfolio management and Lilly's Chorus R&D...
18:06 , Jun 29, 2018 |  BC Week In Review  |  Company News

Renal plays Akebia, Keryx merging

Akebia Therapeutics Inc. (NASDAQ:AKBA) will merge with Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) in an all-stock deal, forming a combined company with one chronic kidney disease compound on the market and another in Phase III testing. Keryx...
22:09 , Jun 28, 2018 |  BC Extra  |  Company News

Renal plays Akebia, Keryx merging

Akebia Therapeutics Inc. (NASDAQ:AKBA) will merge with Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) in an all-stock deal, forming a combined company with one chronic kidney disease compound on the market and another in Phase III testing. The...
17:58 , Mar 30, 2018 |  BC Week In Review  |  Financial News

Akebia raises $89.3M in follow-on

Kidney disease company Akebia Therapeutics Inc. (NASDAQ:AKBA) raised $89.3 million on March 23 through the sale of 8.5 million shares at $10.50 in a follow-on underwritten by Morgan Stanley. The price is a 10% discount...
16:24 , Mar 23, 2018 |  BC Extra  |  Financial News

Akebia raises $89.3M in follow-on

Akebia Therapeutics Inc. (NASDAQ:AKBA) raised $89.3 million through the sale of 8.5 million shares at $10.50 in a follow-on underwritten by Morgan Stanley. The price is a 10% discount to Akebia's close of $11.68 on...
20:17 , Jan 26, 2018 |  BC Week In Review  |  Clinical News

Akebia's vadadustat meets in Phase II dialysis-dependent CKD

Akebia Therapeutics Inc. (NASDAQ:AKBA) reported top-line data from a double-blind, Japanese Phase II study in 60 patients with anemia associated with dialysis-dependent chronic kidney disease (CKD) showing that 150, 300 and 600 mg doses of...
20:46 , Nov 10, 2017 |  BC Week In Review  |  Financial News

Invirsa raises $520K in seed round

Infectious disease play Invirsa Inc. (Columbus, Ohio) raised $520,000 in a seed financing led by CincyTech. Initial investor Rev1 Ventures also participated. Invirsa's lead candidate, INV-102, is in preclinical testing to treat acute conjunctivitis and...
00:30 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

Akebia's vadadustat meets in Phase II for non-dialysis-dependent CKD

Akebia Therapeutics Inc. (NASDAQ:AKBA) said oral vadadustat met the primary endpoint of improving mean hemoglobin levels in a Phase II trial to treat anemia in non-dialysis-dependent patients with chronic kidney disease (CKD). Top-line data from...